Zevin Asset Management LLC reduced its stake in GlaxoSmithKline PLC (NYSE:GSK) by 4.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 54,481 shares of the pharmaceutical company’s stock after selling 2,802 shares during the period. Zevin Asset Management LLC’s holdings in GlaxoSmithKline PLC were worth $2,349,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the company. Bingham Osborn & Scarborough LLC purchased a new stake in shares of GlaxoSmithKline PLC during the second quarter valued at $311,000. 10 15 Associates Inc. boosted its stake in shares of GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares during the period. Lincluden Management Ltd. boosted its stake in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares during the period. Anchor Capital Advisors LLC boosted its stake in shares of GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares during the period. Finally, BlueCrest Capital Management Ltd boosted its stake in shares of GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares during the period. Institutional investors and hedge funds own 9.28% of the company’s stock.

GlaxoSmithKline PLC (NYSE:GSK) opened at 39.905 on Thursday. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54. The company’s 50-day moving average price is $40.70 and its 200 day moving average price is $41.84. The firm has a market capitalization of $97.53 billion, a price-to-earnings ratio of 39.667 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. Analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be issued a $0.491 dividend. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.94%. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/zevin-asset-management-llc-lowers-stake-in-glaxosmithkline-plc-gsk/1533878.html.

GSK has been the subject of a number of analyst reports. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Tuesday, July 18th. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Finally, Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. GlaxoSmithKline PLC has a consensus rating of “Hold” and an average target price of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.